Nu-Med Plus (NUMD) Net Cash Flow Growth (3y) (2015 - 2025)
Nu-Med Plus (NUMD) Net Cash Flow Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.94 Bn | 176.64 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 128.78 Bn | 125.90 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 109.01 Bn | 99.79 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 68.59 Bn | 67.13 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 47.66 Bn | 43.99 Bn | 1.29 Bn | -87.88% |
| 6 | GE HealthCare Technologies | 28.36 Bn | 26.07 Bn | 1.98 Bn | -65.12% |
| 7 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn | 129.29% |
| 8 | Smith & Nephew | 26.93 Bn | 26.36 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn | -48.90% |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | 62.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 62.51% |
| Sep 30, 2025 | -172.24% |
| Dec 31, 2024 | 56.43% |
| Jun 30, 2024 | 67.34% |
| Mar 31, 2024 | 79.09% |
| Dec 31, 2023 | -26.56% |
| Sep 30, 2023 | -39.98% |
| Jun 30, 2023 | -23.59% |
| Mar 31, 2023 | -55.95% |
| Dec 31, 2022 | 11.09% |
| Sep 30, 2022 | -71.15% |
| Jun 30, 2022 | 30.60% |
| Mar 31, 2022 | 60.14% |
| Dec 31, 2021 | -199.71% |
| Sep 30, 2021 | 30.12% |
| Jun 30, 2021 | -92.37% |
| Mar 31, 2021 | 13.33% |
| Dec 31, 2020 | 67.44% |
| Sep 30, 2020 | -44.15% |
| Jun 30, 2020 | 39.06% |